HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Multifunctional Dextran Sulfate-Coated Reconstituted High Density Lipoproteins Target Macrophages and Promote Beneficial Antiatherosclerotic Mechanisms.

Abstract
An atorvastatin calcium (AT)-loaded dextran sulfate (DXS)-coated core-shell reconstituted high density lipoprotein (rHDL), termed AT-DXS-LP-rHDL, was developed for targeted drug delivery to macrophages and suppression of inflammation via the high affinity of DXS with scavenge receptor class AI (SR-AI) as well as depletion of intracellular cholesterol by apolipoprotein A-I (apoA-I)-mediated cholesterol efflux. These core-shell nanoparticles comprising an AT-loaded negatively charged poly(lactide-co-glycolide) (PLGA) core and a cationic lipid bilayer shell were prepared by nanoprecipitation method followed by thin film hydration and extrusion. The nanoparticles were further functionalized with apoA-I and DXS via sodium cholate mediation and electrostatic interaction, respectively. The core-shell structure and the surface coating of apoA-I and DXS were verified by the increased particle size, inverted zeta potential, and reduced in vitro drug release rate. The TEM image further confirmed the entrapment of the PLGA nanoparticles in the aqueous interior of the liposomes. In vitro cell viability assay showed the biocompatibility of the AT-loaded nanocarriers. The cellular uptake study illustrated that the targeting efficacy to macrophages increased in the following order: PLGA nanoparticles (P-NP), core-shell nanoparticles (LP-NP), core-shell rHDL (LP-rHDL), and DXS-LP-rHDL. Moreover, cellular drug efficacy of AT-loaded nanoparticles in preventing macrophage-derived foam cell formation and inflammation such as intracellular lipid deposition, cholesterol esters content, DiI-oxLDL uptake, cholesterol efflux, and secretion of TNF-α, IL-6, and IL-10 was much better than that of the drug-free nanoparticles, consistent with the results of cellular uptake study. Collectively, AT-DXS-LP-rHDL, as multifunctional carriers, could not only deliver more drug to macrophages, but also present antiatherogenic actions of the biofunctional nanocarriers through damping oxidized low density lipoproteins (oxLDL) uptake and promoting cholesterol efflux.
AuthorsYi Zhao, Cuiping Jiang, Jianhua He, Qing Guo, Jing Lu, Yun Yang, Wenli Zhang, Jianping Liu
JournalBioconjugate chemistry (Bioconjug Chem) Vol. 28 Issue 2 Pg. 438-448 (02 15 2017) ISSN: 1520-4812 [Electronic] United States
PMID28004910 (Publication Type: Journal Article)
Chemical References
  • Drug Carriers
  • Interleukin-6
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Tumor Necrosis Factor-alpha
  • oxidized low density lipoprotein
  • Interleukin-10
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
  • Dextran Sulfate
  • Cholesterol
  • Atorvastatin
Topics
  • Animals
  • Atherosclerosis (drug therapy)
  • Atorvastatin (chemistry, pharmacology, therapeutic use)
  • Biological Transport
  • Cholesterol (metabolism)
  • Dextran Sulfate (chemistry)
  • Drug Carriers (chemistry, metabolism)
  • Humans
  • Interleukin-10 (metabolism)
  • Interleukin-6 (metabolism)
  • Intracellular Space (metabolism)
  • Lactic Acid (chemistry)
  • Lipoproteins, HDL (chemistry)
  • Lipoproteins, LDL (metabolism)
  • Macrophages (metabolism)
  • Mice
  • Models, Molecular
  • Polyglycolic Acid (chemistry)
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Protein Conformation
  • RAW 264.7 Cells
  • Surface Properties
  • Tumor Necrosis Factor-alpha (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: